Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Related articles

VOLUME 13 , ISSUE 3 ( September, 2009 ) > List of Articles

CASE REPORT

Concurrent administration of heparin and activated protein C in a patient with pulmonary embolism and severe sepsis with positive outcome

Palepu B. Gopal, S. Mohan, Vivek V. Veturi

Keywords : Activated protein C, heparin, pulmonary embolism, severe sepsis

Citation Information : Gopal PB, Mohan S, Veturi VV. Concurrent administration of heparin and activated protein C in a patient with pulmonary embolism and severe sepsis with positive outcome. Indian J Crit Care Med 2009; 13 (3):163-166.

DOI: 10.4103/0972-5229.58544

License: CC BY-ND 3.0

Published Online: 00-09-2009

Copyright Statement:  Copyright © 2009; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Results of the PROWESS trial suggested that heparin may reduce the efficacy of recombinant human activated protein C (rhAPC) and the XPRESS study also showed increased bleeding complications in patients receiving heparin with rhAPC. Although it has been shown that heparin prophylaxis may be used along with rhAPC, no study has shown the interaction between continuous heparin infusion and rhAPC. Here, we report a case of severe sepsis with pulmonary embolism who was concurrently administered heparin and rhAPC infusions, with positive results and no bleeding complications.


PDF Share
  1. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
  2. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
  3. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 1998;24:663-72.
  4. Early intravenous unfractionated heparin and mortality in septic shock. Crit Care Med 2008;36:2973-9.
  5. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA 2003;290:238-47.
  6. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med 2007;176:483-90.
  7. Heparin: The cheap alternative for immunomodulation in sepsis? Crit Care Resusc 2006;8:235-8.
  8. Heparin-protein C interaction. Nouv Rev Fr Hematol 1984;26:239-42.
  9. Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein. J Clin Invest 1997;99:2655-63.
  10. Effect of recombinant activated protein C and low-dose heparin on neutrophil-endothelial cell interactions in septic shock. Crit Care Med 2006;34:2207-12.
  11. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT. Thromb Res 2007;119:361-7.
  12. The effect of activated protein C on plasma plasminogen activator inhibitor activity in patients with acute myocardial infarction treated with alteplase: Comparison with unfractionated heparin. J Am Coll Cardiol 2003;42:1389-94.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.